ERBB2 and mucinous adenocarcinoma: Despite being uncommon (approximately 3 to 4%), mucinous carcinoma is molecularly unique, exhibiting high rates of KRAS mutations, TP53 alterations, and sporadic HER2 (Erbb2) amplification [51].